Back
45
Day Range
$9.81
$10.00
52-Week Range
$1.50
$12.53
Volume
1,000
50D / 200D Avg
$10.12
/
$8.12
Prev Close
$10.00
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (625 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 8.2 | 14.0 |
| P/B | 2.8 | 2.4 |
| ROE % | 25.5 | 11.4 |
| Net Margin % | 21.8 | 10.1 |
| Rev Growth 5Y % | 22.1 | 7.0 |
| D/E | 1.3 | 0.5 |
Key Takeaways
Revenue grew 22.12% annually over 5 years — strong growth
ROE of 25.45% indicates high profitability
Net margin of 21.79% shows strong profitability
Negative free cash flow of -1.44B
P/E of 8.17 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 63.08%
Growth
Revenue Growth (5Y)
22.12%
Revenue (1Y)85.20%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
25.45%
ROIC11.32%
Net Margin21.79%
Op. Margin22.19%
Safety
Debt / Equity
1.34
Current Ratio1.05
Interest Coverage0.00
Valuation
P/E Ratio
8.17
P/B Ratio2.84
EV/EBITDA10.74
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 85.20% | Revenue Growth (3Y) | 71.55% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 22.12% | Earnings Growth (5Y) | 25.72% |
| Profitability | |||
| Revenue (TTM) | 3.17B | Net Income (TTM) | 690.24M |
| ROE | 25.45% | ROA | 12.55% |
| Gross Margin | 0.00% | Operating Margin | 22.19% |
| Net Margin | 21.79% | Free Cash Flow (TTM) | -1.44B |
| ROIC | 11.32% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.34 | Current Ratio | 1.05 |
| Interest Coverage | 0.00 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 8.17 | P/B Ratio | 2.84 |
| P/S Ratio | 1.78 | PEG Ratio | -0.37 |
| EV/EBITDA | 10.74 | Dividend Yield | 0.00% |
| Market Cap | 5.64B | Enterprise Value | 7.55B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.17B | 1.71B | 1.08B | 767.78M | 1.42B |
| Net Income | 690.24M | -1.47B | -1.51B | -998.83M | 276.26M |
| EPS (Diluted) | 1.26 | -2.73 | -2.80 | -1.88 | 0.57 |
| Gross Profit | 0.0 | 1.37B | 822.99M | 497.84M | 1.36B |
| Operating Income | 702.81M | -1.37B | -1.50B | -1.05B | 162.84M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 5.50B | 5.53B | 6.02B | 4.16B | 4.12B |
| Total Liabilities | 3.51B | 2.09B | 1.04B | 712.79M | 523.07M |
| Shareholders' Equity | 1.99B | 3.44B | 4.98B | 3.45B | 3.59B |
| Total Debt | 2.67B | 1.26B | 165.04M | 102.78M | 197.69M |
| Cash & Equivalents | 759.53M | 709.07M | 2.07B | 1.76B | 2.77B |
| Current Assets | 2.29B | 2.23B | 3.21B | 2.30B | 2.98B |
| Current Liabilities | 2.19B | 1.14B | 892.30M | 616.40M | 431.29M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#193 of 654
Recent Activity
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026